NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

HOOK

Hookipa Pharma Inc

May 09 • 12:09PM ET

1.41

Dollar change -0.06
Percentage change -4.08	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN AMGN VRTX BIIB CRSP ARWR SGMO PTGX RDUS

| Held by: VTI VXF DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.55	Insider Own	42.77%	Shs Outstand	9.66M	Perf Week	5.22%
Market Cap	17.18M	Forward P/E	-	EPS next Y	-1.70	Insider Trans	0.00%	Shs Float	6.97M	Perf Month	79.39%
Income	-43.50M	PEG	-	EPS next Q	-1.04	Inst Own	23.84%	Short Float	0.19%	Perf Quarter	-20.79%
Sales	43.95M	P/S	0.39	EPS this Y	11.24%	Inst Trans	5.43%	Short Ratio	0.16	Perf Half Y	-62.99%
Book/sh	4.25	P/B	0.33	EPS next Y	44.81%	ROA	-35.68%	Short Interest	0.01M	Perf Year	-98.30%
Cash/sh	3.27	P/C	0.43	EPS next 5Y	26.11%	ROE	-61.68%	52W Range	0.72 - 105.00	Perf YTD	-29.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.13%	ROI	-84.41%	52W High	-98.66%	Beta	0.71
Dividend TTM	-	Quick Ratio	3.27	Sales past 5Y	39.00%	Gross Margin	93.74%	52W Low	95.56%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	3.27	EPS Y/Y TTM	61.16%	Oper. Margin	-101.91%	RSI (14)	63.90	Volatility	19.09% 13.65%
Employees	87	Debt/Eq	0.02	Sales Y/Y TTM	118.32%	Profit Margin	-98.99%	Recom	3.00	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	17.48%	Payout	-	Rel Volume	1.79	Prev Close	1.47
Sales Surprise	-60.90%	EPS Surprise	-73.60%	Sales Q/Q	-81.72%	Earnings	Feb 28 BMO	Avg Volume	81.64K	Price	1.41
SMA20	38.70%	SMA50	29.48%	SMA200	-50.16%	Trades		Volume	64,908	Change	-4.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$48 → $2
Nov-15-24	Reiterated	RBC Capital Mkts	Outperform	$50 → $48
Dec-02-22	Downgrade	BofA Securities	Buy → Underperform	$0.50
Dec-02-22	Downgrade	BofA Securities	Buy → Underperform
Nov-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$6
Apr-08-21	Initiated	Morgan Stanley	Overweight	$19
Nov-03-20	Initiated	Truist	Buy	$21
Oct-26-20	Initiated	JMP Securities	Mkt Outperform	$19
Oct-19-20	Resumed	H.C. Wainwright	Buy	$16
Sep-27-19	Initiated	H.C. Wainwright	Buy	$15
May-13-19	Initiated	RBC Capital Mkts	Outperform	$23
May-13-19	Initiated	BofA/Merrill	Buy	$17

Show Previous Ratings

Feb-20-25 03:06PM	HOOKIPA Pharma Inc. ( HOOKIPA ) Statement regarding potential combination for Poolbeg Pharma plc ( Poolbeg ) (GlobeNewswire)
Jan-31-25 07:21AM	Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial (TipRanks)
Jan-30-25 07:00AM	HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV (GlobeNewswire)
Jan-10-25 02:00AM	Poolbeg Pharma plc ( Poolbeg ) and HOOKIPA Pharma Inc. ( HOOKIPA ) Update on Potential Combination of Poolbeg and HOOKIPA (GlobeNewswire) +15.59%
Jan-08-25 11:23AM	HOOKIPA Pharma Inc - FORM 8 (OPD) (GlobeNewswire)
04:05PM	Loading…
Jan-07-25 04:05PM	HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements (GlobeNewswire)
02:00AM	Poolbeg Pharma plc ( Poolbeg ) and HOOKIPA Pharma Inc. ( HOOKIPA ) Update on Potential Combination of Poolbeg and HOOKIPA (GlobeNewswire)
Jan-06-25 02:00AM	HOOKIPA Pharma Inc. ( HOOKIPA ) Rule 2.9 Announcement Amendment (GlobeNewswire)
Jan-02-25 02:00AM	Poolbeg Pharma plc ( Poolbeg or the Company ) Combination of Poolbeg and HOOKIPA Pharma Inc. (GlobeNewswire)
Nov-22-24 06:51AM	Hookipa Pharma price target lowered to $7 from $24 at JMP Securities (TipRanks) -6.52%
06:35AM	Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program (TipRanks)
Nov-14-24 04:05PM	HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates (GlobeNewswire) -8.19%
Nov-11-24 04:05PM	HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker (GlobeNewswire)
Oct-31-24 09:17AM	HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 (GlobeNewswire)
Oct-30-24 07:30AM	HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer (GlobeNewswire)
07:30AM	Loading…
Sep-24-24 07:30AM	HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset (GlobeNewswire)
Sep-02-24 09:55AM	Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet (Zacks)
Aug-30-24 08:00AM	HOOKIPA Pharma Announces Board of Directors Changes (GlobeNewswire)
Aug-28-24 08:57AM	HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.50%
Aug-08-24 04:30PM	HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.11%
Aug-07-24 09:55AM	Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade (Zacks)
Aug-01-24 10:01AM	Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know (Zacks) -5.67%
Jul-22-24 08:30AM	HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 (GlobeNewswire)
Jul-08-24 07:01AM	HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split (GlobeNewswire) -9.33%
Jul-02-24 06:32AM	HOOKIPA Pharma doses first subject in Phase Ib HIV treatment trial (Clinical Trials Arena) -7.43%
Jul-01-24 04:31PM	HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV (GlobeNewswire) +6.17%
Jun-04-24 01:00PM	HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting (GlobeNewswire) -8.06%
May-30-24 04:30PM	HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting (GlobeNewswire) +5.63%
May-23-24 05:01PM	HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting (GlobeNewswire) +6.12% -23.08%
May-16-24 02:27PM	Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch (InvestorPlace) -5.59%
11:55AM	Loading…
May-09-24 11:55AM	HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:01AM	HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-25-24 07:01AM	HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab (GlobeNewswire) -5.16%
Apr-24-24 12:31PM	Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? (Benzinga) +11.11%
07:01AM	HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers (GlobeNewswire)
Apr-16-24 04:30PM	HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.57% -5.85%
Apr-10-24 07:01AM	HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration (GlobeNewswire)
Mar-22-24 01:52PM	HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:01AM	HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-06-24 07:01AM	HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-02-24 12:00PM	All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy (Zacks) +6.23%
Jan-29-24 08:01AM	HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs (GlobeNewswire) -10.10%
Jan-16-24 07:01AM	HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization (GlobeNewswire) -9.11%
Dec-21-23 09:15AM	Why Is Hookipa Pharma (HOOK) Stock Up 81% Today? (InvestorPlace) +52.65%
07:01AM	HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences (GlobeNewswire)
Nov-20-23 07:01AM	HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus (GlobeNewswire)
Nov-09-23 08:39AM	HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023 (GuruFocus.com) -11.97%
07:01AM	HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-23 12:01PM	HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023 (GlobeNewswire) +7.16%
Nov-02-23 04:01PM	HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023 (GlobeNewswire)
Oct-22-23 06:01AM	HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023 (GlobeNewswire)
Oct-18-23 07:01AM	HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences (GlobeNewswire)
Sep-13-23 08:45AM	HOOKIPA Announces Executive Leadership Change (GlobeNewswire)
Sep-12-23 07:01AM	HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-23 08:17PM	7 Biotech Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
07:01AM	HOOKIPA Pharma to participate in upcoming investor conferences in September (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 08:40AM	HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:01AM	HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-03-23 07:01AM	HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023 (GlobeNewswire)
Jul-12-23 07:22AM	Daily Vickers Top Buyers & Sellers for 07/12/2023 (Argus Research) +6.17%
Jun-10-23 05:00AM	HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-31-23 09:30PM	HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock (GlobeNewswire) -5.76% -14.50%
04:45PM	HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers (GlobeNewswire)
May-16-23 06:08AM	Revenue Downgrade: Here's What Analysts Forecast For HOOKIPA Pharma Inc. (NASDAQ:HOOK) (Simply Wall St.) -15.05%
May-11-23 08:25AM	HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:01AM	HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
May-09-23 05:35PM	Mirati (MRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +26.77% -5.34%
07:01AM	HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B (GlobeNewswire)
May-04-23 07:02AM	HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May (GlobeNewswire) +13.33%
07:01AM	HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023 (GlobeNewswire)
Apr-26-23 11:30AM	HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO (GlobeNewswire) +6.20%
Apr-19-23 07:00AM	HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference (GlobeNewswire)
Apr-14-23 04:01PM	HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-23 03:12AM	HOOKIPA Pharma Inc. (NASDAQ:HOOK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:35AM	HOOKIPA Pharma Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-16-23 04:18AM	Q4 2022 HOOKIPA Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-15-23 08:15AM	HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook (GlobeNewswire)
Mar-13-23 07:00AM	HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors (GlobeNewswire) -6.65%
Mar-08-23 07:00AM	HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023 (GlobeNewswire)
Feb-13-23 07:00AM	HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers (GlobeNewswire)
Feb-07-23 07:00AM	HOOKIPA to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-04-23 07:00AM	HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine (GlobeNewswire) +7.25%
Dec-20-22 09:11AM	12 Penny Stocks With Biggest Upside (Insider Monkey)
Dec-15-22 07:00AM	HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors (GlobeNewswire)
Nov-30-22 07:00AM	HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-16-22 05:39AM	Analysts Are Betting On HOOKIPA Pharma Inc. (NASDAQ:HOOK) With A Big Upgrade This Week (Simply Wall St.)
Nov-14-22 08:15AM	HOOKIPA Pharma Inc. (HOOK) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.20%
07:00AM	HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
Nov-07-22 10:00AM	AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
07:00AM	HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022 (GlobeNewswire)
Nov-02-22 10:01AM	HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference (GlobeNewswire)
Oct-20-22 07:00AM	HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers (GlobeNewswire)
Sep-29-22 12:00PM	HOOKIPA Pharma Inc. (HOOK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-27-22 08:07AM	Investors in HOOKIPA Pharma (NASDAQ:HOOK) have unfortunately lost 81% over the last three years (Simply Wall St.)
Sep-07-22 07:00AM	HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +5.30%

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. It also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HOOK

Hookipa Pharma Inc

Upgrade your FINVIZ experience